🎯 Jazz Pharmaceuticals has licensed KRAS blockers from Redx Pharma to advance them in clinical development.
💰 Redx Pharma will receive $10 million upfront and up to $870 million in milestone payments.
💊 The KRAS blockers have the potential to improve treatment options for cancer patients.
💰 Redx Pharma will receive $10 million upfront and up to $870 million in milestone payments.
💊 The KRAS blockers have the potential to improve treatment options for cancer patients.
📢 Jazz Pharma’s Million-Dollar Deal for Cancer Breakthrough
Introduction:
Jazz Pharmaceuticals has entered an agreement with Redx Pharma to acquire commercialization rights to Redx KRAS blockers, including G12D selective and pan-KRAS molecules.
Main points:
- Redx Pharma will receive upfront payment of US$10 million and up to US$870 million in milestone payments, as well as royalties based on future net sales.
- Jazz Pharmaceuticals will collaborate with Redx Pharma to advance candidates through IND-enabling studies and will be responsible for clinical development, regulatory activities, manufacturing, and commercialization.
- The collaboration aims to identify and advance the most promising KRAS molecules for cancer treatment.
- KRAS inhibitors targeting commonly occurring mutations may offer treatment options for colorectal, pancreatic, and lung cancer patients.
Conclusion:
The agreement between Jazz Pharmaceuticals and Redx Pharma will allow the development of KRAS blockers for the treatment of various cancers, potentially improving treatment options for patients with limited options.
